Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of ...
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: GlobeNewswire
As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with MASLD and T2DA significantly higher proportion of patients achieved a greater than 30% liver triglyceride reduction as well as MASLD resolution with lanifibranor compared to placeboLanifibranor treatment significantly improved both hepatic and peripheral insulin sensitivity (i.e. fasting plasma insulin, fasting hepatic glucose production, hepatic insulin resistance index, insulin-stimulated muscle glucose disposal), which translated into better glycemic control (i.e. HbA1c)The study met multiple secondary metabolic endpoints confirming the cardiometabolic benefit of lanifibranor in patients with MASLD, and ability to improve adipose tissue function The study confirmed the favorable safety and tolerability profile of lanifibr
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Inventiva to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025GlobeNewswire
- Inventiva reports 2025 Third Quarter Financial Information¹GlobeNewswire
- Inventiva (NASDAQ:IVA) had its price target lowered by analysts at Guggenheim from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5MGlobeNewswire
IVA
Earnings
- 9/29/25 - Miss
IVA
Sec Filings
- 11/28/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/19/25 - Form SCHEDULE
- IVA's page on the SEC website